96-Well Chromatin Immunoprecipitation (ChIP) Assay
Porvair Sciences has announced an application note describing the excellent results achievable from a new 96-well format version of its ChromaTrap chromatin immunoprecipitation (ChIP) assay technology.
Developments in the field of epigenetics are rapidly expanding as researchers elucidate the principles governing gene regulation through the in vivo dynamic binding of proteins to DNA. Key to this is the need to analyse large numbers of high and low abundant regulatory mechanisms to systematically map protein-DNA interactions following pathogen/disease stimulus.
Chromatin immunoprecipitation (ChIP) assays are used to study these associations and have been historically limited to large sample numbers, onerous washing steps resulting in valuable sample losses and low signal to noise coupled with poor reproducibility. This new application note details the use of Chromatrap 96 Pro-A, a 96-well plate, each well of which contains a solid phase rigid porous polymer, BioVyon, to which Protein A is chemically bound, allowing up to 96 ChIP assays to be run in parallel on the same plate.
To determine ease of use, experimental design flexibility and reproducibility in screening multiple epigenetic targets with Chromatrap 96, the binding efficiency and occupancy of common epigenetic marks (H3, H4, H3K4me3 and RNA pol II) on three gene targets of interest (GAPDH, beta-globin, and PABPC1) in three human chromatin samples (HepG2, HeLa and K562) were performed simultaneously on the 96-well plate and analysed using qPCR. The application note describes in detail the analytical methodology, data interpretation and statistical analysis, as well as the benefits of using the new Chromatrap 96 high throughput ChIP assay plate, which include multiple target screening, flexible experimental design, robust reproducibility, high data quality and automated liquid handling potential.
To download a copy of this new application note, click here.
For further information or to discuss your application with technical product specialists please contact Porvair Sciences on +44 1372 824 290 / [email protected]
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance